Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice

Bibliography

• Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010;375:1212-23
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA, A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40
   PubMed Web of Science ®Google Scholar
• Marinelli A, Capucci A. Antiarrhythmic drugs for atrial fibrillation. Expert Opin Pharmacother 2011;12(8):1201-1215
   Google Scholar
• Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008;1:62-73
   PubMed Web of Science ®Google Scholar
• Dobrev D, Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol 2008;52:293-9
   PubMed Web of Science ®Google Scholar
• Sood S, Chelu MG, van Oort RJ, Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. Heart Rhythm 2008;5:1047-54
   PubMed Web of Science ®Google Scholar
• Michael G, Xiao L, Qi XY, Remodeling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis. Cardiovasc Res 2009;81:491-9
   Google Scholar
• Chelu MG, Sarma S, Sood S, Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest 2009;119:1940-51
   PubMed Web of Science ®Google Scholar
• Dobrev D. Electrical remodeling in atrial fibrillation. Herz 2006;31:108-12
   Google Scholar
• Dobrev D, Voigt N, Wehrens XH. The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res 2010;89(4):734-43
   Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M, Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
   PubMed Web of Science ®Google Scholar
• Hammwohner M, Goette A. Will warfarin soon be passe? New approaches to stroke prevention in atrial fibrillation. J Cardiovasc Pharmacol 2008;52:18-27
   Web of Science ®Google Scholar
• Lamassa M, Di Carlo A, Pracucci G, Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001;32:392-8
   PubMed Web of Science ®Google Scholar
• Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007;3:CD006186
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, James KE, Nazarian SM, Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation 1995;92(8):2178-82
   PubMed Web of Science ®Google Scholar
• Knecht S, Oelschlager C, Duning T, Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008;29:2125-32
   PubMed Web of Science ®Google Scholar
• van Walraven C, Hart RG, Singer DE, Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8
   PubMed Web of Science ®Google Scholar
• Connolly S, Pogue J, Hart R, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12
   PubMed Web of Science ®Google Scholar
• Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006;118:321-33
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):204S-33S
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Nagarakanti R, Ezekowitz MD, Oldgren J, Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-6
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation The HAS-BLED (hypertension,abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 2011;57:173-80
   PubMed Web of Science ®Google Scholar
• Themistoclakis S, Corrado A, Marchlinski FE, The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010;55:735-43
   PubMed Web of Science ®Google Scholar